Abivax S.A.
ABVX
주식 순위
#2416
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
주가
$93.77
시가총액
$8.18B
변동 (1일)
-1.01%
변동 (1년)
6.11%
국가
FR
거래 Abivax S.A. (ABVX)
카테고리
Healthcare
Abivax S.A. (ABVX)의 수익
2026 기준 수익 TTM: 0
Abivax S.A.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Abivax S.A.의 수익 기록 (2013 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2025 | $-391.07M | 105.49% |
| 2024 | $-190.31M | 13.09% |
| 2023 | $-168.29M | 140.56% |
| 2022 | $-69.96M | 35.02% |
| 2021 | $-51.81M | 6.02% |
| 2020 | $-48.87M | 24.83% |
| 2019 | $-39.15M | 72.11% |
| 2018 | $-22.75M | 36.24% |
| 2017 | $-16.70M | -10.99% |
| 2016 | $-18.76M | -8.06% |
| 2015 | $-20.40M | 229.39% |
| 2014 | $-6.19M | -40.41% |
| 2013 | $-10.39M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
